Premium
Lifestyle Changes in African Americans and Whites Following a Diagnosis of Prostate Cancer: Rationale, Objectives, and Study Design
Author(s) -
Paxton Amy,
Steck Susan E,
Kupper Lawrence,
Arab Lenore,
Satia Jessie
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.4.a152-b
Subject(s) - medicine , prostate cancer , cancer , gerontology , anthropometry , psychological intervention , incidence (geometry) , demography , prostate cancer screening , prostate specific antigen , physics , psychiatry , sociology , optics
Prostate Cancer (CaP) is the most common cancer in men and the second leading cause of cancer mortality. African Americans (AA) have the highest prostate cancer (CaP) incidence and mortality rates among all racial groups. Research suggests that lifestyle changes may influence CaP outcomes post‐diagnosis. The objectives of this study are to 1) assess changes in modifiable lifestyle factors post‐diagnosis and determine whether changes differ by race, and 2) examine the extent to which lifestyle changes may influence CaP outcomes as measured by changes in serum PSA. This report discusses the study rationale, objectives, and design. Newly diagnosed AA and White prostate cancer patients in North Carolina (n=250) will be followed for 2 years. Participants will complete three 24‐hour dietary recalls between 6 and 12 months post‐diagnosis. At 12‐ months and 24‐months post‐diagnosis, in‐home interviews will be conducted with anthropometric measurements; questionnaires related to dietary intake, physical activity, and dietary supplements; and collection of biologic samples. Longitudinal data analysis methods will be used to examine changes in these lifestyle factors post‐diagnosis in relation to serum PSA levels. Data collection is underway and results are expected in 2007. Identification of modifiable lifestyle factors that affect CaP outcomes post‐diagnosis and any differences by race may provide information that can be used to develop appropriate interventions to reduce racial disparities in CaP prognosis and lower the risk of fatal prostate cancer. This work is supported in part by grants from the DoD (PC030770) and NIH (538444).